
Benign Conditions
Latest News
Latest Videos

CME Content
More News

The approval of oral sulopenem was supported by data from the phase 3 SURE 1 (NCT03366207) and REASSURE (NCT05584657) trials.

The target action date for the application is December 11, 2025.

Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.

Sonam Saxena highlights a study on factors that may predict failure of robotic ureteroplasty with buccal mucosa graft.

FDA accepts new drug application for zoliflodacin for uncomplicated gonorrhea
The NDA is supported by a pivotal phase 3 trial of zoliflodacin vs ceftriaxone plus azithromycin in patients with uncomplicated gonorrhea.

These data are intended to support a new drug application to the FDA in the second half of 2025.

A recap of the FDA submissions and regulatory decisions in urology from April 2025.

The method involves local delivery of the antibiotic gentamicin directly into the bladder tissue.

Check out the key regulatory decisions set to happen early this year.

In a recent study of the RELIEF stent, 95% of patients showed no VUR following stent placement.

"The goal for this study was to understand, over the lifetime in individuals with spina bifida, what bacteria are present in their urine normally, what bacteria are present when they have a UTI, and what are some important clinical differences we can tease out to help understand which patients should really be treated," says Brendan T. Frainey, MD.

Catch up on all the notable drug and device approvals in urology over the past year.

A rapid reduction in E coli in the urine was observed among 10 of 16 evaluable patients at 4 hours following the first treatment.

FDA approves oral sulopenem for uncomplicated urinary tract infection
The approval is supported by data from the phase 3 SURE 1 and REASSURE trials.

According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by underactive bladder.”

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

















